Filing Flows › Corcept Therapeutics (CORT) › R&D spending
Corcept Therapeutics (CORT) R&D spending by quarter
Corcept Therapeutics' R&D spending was $56.7M in Q3 2026 (third quarter 2026), +5% from Q2 2026. Over the last 7 quarters it ranged from $53.9M (Q2 2026) to $68.8M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $56.7M | +5% | -18% |
| Q2 2026 | $53.9M | -19% | -11% |
| Q1 2026 | $66.3M | +2% | +9% |
| Q4 2025 | $64.9M | -6% | — |
| Q3 2025 | $68.8M | +14% | — |
| Q2 2025 | $60.5M | -0.4% | — |
| Q1 2025 | $60.7M | — | — |
Q3 2026 at a glance
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Questions
What is Corcept Therapeutics' R&D spending?
Corcept Therapeutics' R&D spending was $56.7M in Q3 2026 (third quarter 2026), +5% from Q2 2026.
How has Corcept Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $53.9M (Q2 2026) to $68.8M (Q3 2025).